HRP20240475T8 - A1at za smanjenje rizika od nastanka akutne bolesti graft versus host nakon transplantacije hematopoetskih stanica - Google Patents

A1at za smanjenje rizika od nastanka akutne bolesti graft versus host nakon transplantacije hematopoetskih stanica Download PDF

Info

Publication number
HRP20240475T8
HRP20240475T8 HRP20240475TT HRP20240475T HRP20240475T8 HR P20240475 T8 HRP20240475 T8 HR P20240475T8 HR P20240475T T HRP20240475T T HR P20240475TT HR P20240475 T HRP20240475 T HR P20240475T HR P20240475 T8 HRP20240475 T8 HR P20240475T8
Authority
HR
Croatia
Prior art keywords
a1at
risk
reducing
host disease
cell transplantation
Prior art date
Application number
HRP20240475TT
Other languages
English (en)
Croatian (hr)
Inventor
Marc UKNIS
Christine VOIGT
Gautam BAHETI
John Roberts
Original Assignee
Csl Behring Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Csl Behring Llc filed Critical Csl Behring Llc
Publication of HRP20240475T1 publication Critical patent/HRP20240475T1/hr
Publication of HRP20240475T8 publication Critical patent/HRP20240475T8/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Transplantation (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Materials For Medical Uses (AREA)
HRP20240475TT 2017-12-01 2018-11-30 A1at za smanjenje rizika od nastanka akutne bolesti graft versus host nakon transplantacije hematopoetskih stanica HRP20240475T8 (hr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201762593446P 2017-12-01 2017-12-01
US201862729376P 2018-09-10 2018-09-10
EP18821851.5A EP3716998B1 (en) 2017-12-01 2018-11-30 A1at for reducing risk of onset of acute graft versus host disease after hematopoeitic cell transplantation
PCT/US2018/063179 WO2019108865A1 (en) 2017-12-01 2018-11-30 Methods for reducing risk of onset of acute graft versus host disease after hematopoeitic cell transplantation

Publications (2)

Publication Number Publication Date
HRP20240475T1 HRP20240475T1 (hr) 2024-07-05
HRP20240475T8 true HRP20240475T8 (hr) 2024-08-02

Family

ID=64734181

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20240475TT HRP20240475T8 (hr) 2017-12-01 2018-11-30 A1at za smanjenje rizika od nastanka akutne bolesti graft versus host nakon transplantacije hematopoetskih stanica

Country Status (13)

Country Link
US (2) US11857610B2 (https=)
EP (2) EP4321220B1 (https=)
JP (2) JP2021505545A (https=)
AU (1) AU2018374285B2 (https=)
DK (1) DK3716998T3 (https=)
ES (2) ES2975208T3 (https=)
FI (1) FI3716998T3 (https=)
HR (1) HRP20240475T8 (https=)
HU (1) HUE066011T2 (https=)
PL (1) PL3716998T3 (https=)
PT (1) PT3716998T (https=)
SI (1) SI3716998T1 (https=)
WO (1) WO2019108865A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021028927A1 (en) * 2019-08-15 2021-02-18 Kamada Ltd Combination of alpha-1-antitrypsin and steroids and uses therefor
WO2023056075A1 (en) * 2021-10-01 2023-04-06 The Regents Of The University Of Colorado, A Body Corporate Compositions and methods for reduced toxicity in transplantation using janus kinase (jak) inhibitors

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9457070B2 (en) * 2005-06-07 2016-10-04 The Regents Of The University Of Colorado, A Body Corporate Compositions, methods and uses of alpha 1-antitrypsin for early intervention in bone marrow transplantation and treatment of graft versus host disease
US8715649B2 (en) 2005-06-07 2014-05-06 The Regents Of The University Of Colorado, A Body Corporate Compositions and methods of use for alpha-1 antitrypsin having no significant serine protease inhibitor activity
US20090118162A1 (en) 2005-06-07 2009-05-07 Regents Of The University Of Colorado Inhibitors of serine protease activity and their use in methods and compositions for treatment of graft rejection and promotion of graft survival
CN101341254A (zh) * 2005-12-24 2009-01-07 蒂加斯克乳制品研究中心 反-10，顺-12十八碳二烯酸的生产方法
US20090028832A1 (en) * 2006-08-10 2009-01-29 Chung Leland F Compositions and methods for targeted tumor therapy
CA2798518A1 (en) * 2010-05-17 2011-11-24 Cebix, Inc. Pegylated c-peptide
EP3628327A1 (en) * 2011-06-24 2020-04-01 The Regents of the University of Colorado, A Body Corporate Compositions, methods and uses for alpha-1 antitrypsin fusion molecules
US10400029B2 (en) * 2011-06-28 2019-09-03 Inhibrx, Lp Serpin fusion polypeptides and methods of use thereof
CN110551223A (zh) 2011-06-28 2019-12-10 英伊布里克斯有限合伙公司 丝氨酸蛋白酶抑制蛋白融合多肽及其使用方法
AU2013202648B2 (en) 2012-01-10 2016-05-19 Konkuk University Compositions, methods and uses for alpha-1 antitrypsin fusion molecules
ES2799153T3 (es) 2013-03-29 2020-12-15 Univ Colorado Regents Alfa 1 antitripsina para uso en la preparación de un sujeto para trasplante
WO2017117558A1 (en) 2015-12-31 2017-07-06 The Regents Of The University Of Colorado, A Body Corporate Methods and uses for alpha-1 antitrypsin or recombinant forms thereof, on steroid-refractory graft versus host disease involving gastrointestinal complications

Also Published As

Publication number Publication date
SI3716998T1 (sl) 2024-05-31
EP3716998B1 (en) 2024-01-10
PT3716998T (pt) 2024-04-09
EP4321220B1 (en) 2025-10-29
DK3716998T3 (da) 2024-04-02
JP2021505545A (ja) 2021-02-18
JP2024001191A (ja) 2024-01-09
PL3716998T3 (pl) 2024-06-24
US20210008182A1 (en) 2021-01-14
US20240238395A1 (en) 2024-07-18
US11857610B2 (en) 2024-01-02
HUE066011T2 (hu) 2024-07-28
AU2018374285B2 (en) 2024-06-27
ES3059603T3 (en) 2026-03-23
HRP20240475T1 (hr) 2024-07-05
AU2018374285A1 (en) 2020-07-02
WO2019108865A1 (en) 2019-06-06
EP4321220A3 (en) 2024-03-20
EP4321220A2 (en) 2024-02-14
FI3716998T3 (fi) 2024-04-16
EP3716998A1 (en) 2020-10-07
ES2975208T3 (es) 2024-07-04

Similar Documents

Publication Publication Date Title
IL287033A (en) Nuclease-mediated regulation of gene expression
EP3307864A4 (en) CELLAR HOLDER FOR AUTOLOGOUS CELL THERAPY
EP3728560A4 (en) COMPOSITION OF CULTIVATED MEAT
PL3386534T3 (pl) Kompozycje i sposoby internalizacji enzymów
LT3768674T (lt) Aminopirimidino dariniai kaip ctps1 inhibitoriai
EP3445407A4 (en) COMPOSITIONS AND METHODS FOR CELLULAR IMMUNOTHERAPY
EP3547968A4 (en) PROSTHESIS OBTAINED BY TISSUE ENGINEERING
HRP20181630T1 (hr) Postupci i kompoziti za ciljne genetske modifikacije i načini korištenja
EP3256071C0 (en) AORTIC IMPLANT
DK3155101T3 (da) Sammensætninger og fremgangsmåder til ekspression af CRISPR-leder-RNA´er under anvendelse af H1-promotoren
PT3204015T (pt) Composições e métodos para inibição de expressão do gene hao1 (hidroxiácido oxidase 1 (glicolato oxidase))
DK3466432T3 (da) Fremgangsmåder til behandling af pulmonale non-tuberkuløse mykobakterielle infektioner
SI3169328T1 (sl) Derivati kinolina za zdravljenje vnetnih bolezni
IL283332A (en) Compounds and methods for reducing prion expression
EP3496660C0 (en) AORTIC IMPLANT
EP3384051A4 (en) METHOD FOR THE SEX DETERMINATION OF BIRD EMBRYOS IN UNBALANCED EGGS AND AGENTS THEREOF
EP3384038A4 (en) METHOD AND COMPOSITIONS FOR REPROGRAMMING T-CELLS
EP3632376C0 (en) SELF-CURVING STENT
FI3697459T3 (fi) Autologinen luusiirteen korvike
EP3785678A4 (en) STENT
KR20210030271A9 (ko) 스텐트
SI3826997T1 (sl) Postopek in intermediati za pripravo bilastina
EP3645019A4 (en) COMPOSITIONS AND PROCEDURES FOR ADOPTIVE CELL THERAPY
EP4144386C0 (en) BONE GRAFT SUBSTITUTE
HRP20240475T8 (hr) A1at za smanjenje rizika od nastanka akutne bolesti graft versus host nakon transplantacije hematopoetskih stanica